Heart disease experts are hailing the results of a clinical trial showed a strongly positive performance by a drug that ...
Drugs from Novartis, Amgen and now Lilly have proven powerfully effective at reducing Lp(a). Whether that will translate to a ...
CHICAGO — Lepodisiran, a small interfering RNA agent, lowered lipoprotein(a) levels at 180 days, with a reduction of more ...
An experimental drug could be game-changing for millions of Americans with a higher genetic risk of cardiovascular disease.
Eli Lilly's gene-silencing drug lepodisiran has been shown to reduce lipoprotein (a) levels by more than 90% for at least six ...
BMO Capital Markets analysts said the results potentially position lepodisiran as “one of the most durable assets in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback